The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure

Doris Irene Stenver; L Jeppesen; B Nielsen; J Dalsgaard Nielsen; C Haedersdal; J Mehlsen; K Winther; Jørn Dalsgaard Nielsen; K Winther

The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure

Doris Irene Stenver, L Jeppesen, B Nielsen, J Dalsgaard Nielsen, C Haedersdal, J Mehlsen, K Winther, Jørn Dalsgaard Nielsen, K Winther

Research output: Contribution to journal › Journal article › Research › peer-review

10 Citations (Scopus)

Abstract

The influence of erythropoietin therapy on platelet function and fibrinolysis was evaluated in 12 anemic hemodialysis patients. Six months of therapy with human erythropoietin (50 to 80 IU/kg initially) raised the hemoglobin level to 10.8 g/dl but did not increase platelet activity in vivo as measured by beta-thromboglobulin or platelet factor 4. There was no change in the platelet aggregation thresholds in vitro for ADP, adrenaline, thrombin or collagen during treatment. Platelet number and volume were also unaffected. Fibrinolytic activity intensified as erythropoietin treatment proceeded, with a fall of euglobulin clot lysis time and rise in the activity of t-PA. PAI-1 levels also showed a downward trend, without reaching significance. Thus erythropoietin treatment in modest doses does not seem to adversely influence the hemostatic system in patients on hemodialysis.

Original language	English
Journal	International Journal of Artificial Organs
Volume	17
Issue number	3
Pages (from-to)	141-5
Number of pages	5
ISSN	0391-3988
Publication status	Published - 1 Mar 1994

Cite this

@article{53d687f1216248a28fb720a291cf00e3,

title = "The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure",

abstract = "The influence of erythropoietin therapy on platelet function and fibrinolysis was evaluated in 12 anemic hemodialysis patients. Six months of therapy with human erythropoietin (50 to 80 IU/kg initially) raised the hemoglobin level to 10.8 g/dl but did not increase platelet activity in vivo as measured by beta-thromboglobulin or platelet factor 4. There was no change in the platelet aggregation thresholds in vitro for ADP, adrenaline, thrombin or collagen during treatment. Platelet number and volume were also unaffected. Fibrinolytic activity intensified as erythropoietin treatment proceeded, with a fall of euglobulin clot lysis time and rise in the activity of t-PA. PAI-1 levels also showed a downward trend, without reaching significance. Thus erythropoietin treatment in modest doses does not seem to adversely influence the hemostatic system in patients on hemodialysis.",

author = "Stenver, {Doris Irene} and L Jeppesen and B Nielsen and {Dalsgaard Nielsen}, J and C Haedersdal and J Mehlsen and K Winther and Nielsen, {J{\o}rn Dalsgaard} and K Winther",

year = "1994",

month = mar,

day = "1",

language = "English",

volume = "17",

pages = "141--5",

journal = "International Journal of Artificial Organs",

issn = "0391-3988",

publisher = "Wichtig Publishing",

number = "3",

}

TY - JOUR

T1 - The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure

AU - Stenver, Doris Irene

AU - Jeppesen, L

AU - Nielsen, B

AU - Dalsgaard Nielsen, J

AU - Haedersdal, C

AU - Mehlsen, J

AU - Winther, K

AU - Nielsen, Jørn Dalsgaard

AU - Winther, K

PY - 1994/3/1

Y1 - 1994/3/1

N2 - The influence of erythropoietin therapy on platelet function and fibrinolysis was evaluated in 12 anemic hemodialysis patients. Six months of therapy with human erythropoietin (50 to 80 IU/kg initially) raised the hemoglobin level to 10.8 g/dl but did not increase platelet activity in vivo as measured by beta-thromboglobulin or platelet factor 4. There was no change in the platelet aggregation thresholds in vitro for ADP, adrenaline, thrombin or collagen during treatment. Platelet number and volume were also unaffected. Fibrinolytic activity intensified as erythropoietin treatment proceeded, with a fall of euglobulin clot lysis time and rise in the activity of t-PA. PAI-1 levels also showed a downward trend, without reaching significance. Thus erythropoietin treatment in modest doses does not seem to adversely influence the hemostatic system in patients on hemodialysis.

AB - The influence of erythropoietin therapy on platelet function and fibrinolysis was evaluated in 12 anemic hemodialysis patients. Six months of therapy with human erythropoietin (50 to 80 IU/kg initially) raised the hemoglobin level to 10.8 g/dl but did not increase platelet activity in vivo as measured by beta-thromboglobulin or platelet factor 4. There was no change in the platelet aggregation thresholds in vitro for ADP, adrenaline, thrombin or collagen during treatment. Platelet number and volume were also unaffected. Fibrinolytic activity intensified as erythropoietin treatment proceeded, with a fall of euglobulin clot lysis time and rise in the activity of t-PA. PAI-1 levels also showed a downward trend, without reaching significance. Thus erythropoietin treatment in modest doses does not seem to adversely influence the hemostatic system in patients on hemodialysis.

M3 - Journal article

SN - 0391-3988

VL - 17

SP - 141

EP - 145

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

IS - 3

ER -